WallStreetZenWallStreetZen

NYSEMKT: OCX
ONCOCYTE CORP Stock Forecast, Predictions & Price Target

Analyst price target for OCX

Based on 3 analysts offering 12 month price targets for ONCOCYTE CORP.
Min Forecast
$1.40+34.62%
Avg Forecast
$3.22+209.33%
Max Forecast
$6.00+476.92%

Should I buy or sell OCX stock?

Based on 5 analysts offering ratings for ONCOCYTE CORP.
Buy
Strong Buy
2 analysts 40%
Buy
1 analysts 20%
Hold
2 analysts 40%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

OCX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Stephens & Co.
Bottom 42%
42
HoldDowngradesN/AN/A2022-05-24
Piper Sandler
Top 31%
70
Strong BuyMaintains$1.40+34.62%2022-05-16
Needham
Bottom 1%
1
BuyMaintains$2.25+116.35%2022-05-12
KeyBanc
Top 7%
94
HoldDowngradesN/AN/A2022-03-14
Lake Street
Bottom 29%
29
Strong BuyMaintains$6.00+476.92%2022-03-11
Anonymous
Stephens & Co.
Strong BuyInitiates Coverage On$3.10+198.08%2022-01-07

1 of 1

Forecast return on equity

Is OCX forecast to generate an efficient return?
Company
29.13%
Industry
44.71%
Market
38.7%
OCX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OCX forecast to generate an efficient return on assets?
Company
11.34%
Industry
9.49%
OCX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OCX earnings per share forecast

What is OCX's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.22
Avg 2 year Forecast
-$0.08
Avg 3 year Forecast
$0.14

OCX revenue forecast

What is OCX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$26.2M+226.4%
Avg 2 year Forecast
$45.0M+460.61%
Avg 3 year Forecast
$79.0M+884.18%
OCX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OCX revenue growth forecast

How is OCX forecast to perform vs Biotechnology companies and vs the US market?
Company
149.75%
Industry
24.86%
Market
8.39%
OCX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OCX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OCX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OCX$1.04$3.22+209.33%Buy
URGN$5.43$34.00+526.15%Buy
CDXC$1.80$7.00+288.89%Strong Buy
OVID$1.74$2.40+37.93%Hold
ADAG$2.80$15.00+435.71%Strong Buy

ONCOCYTE Stock Forecast FAQ

Is ONCOCYTE Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSEMKT: OCX) stock is to Buy OCX stock.

Out of 5 analysts, 2 (40%) are recommending OCX as a Strong Buy, 1 (20%) are recommending OCX as a Buy, 2 (40%) are recommending OCX as a Hold, 0 (0%) are recommending OCX as a Sell, and 0 (0%) are recommending OCX as a Strong Sell.

What is OCX's earnings growth forecast for 2022-2024?

(NYSEMKT: OCX) ONCOCYTE's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.37%.

ONCOCYTE's earnings in 2022 is -$70,469,000.On average, 1 Wall Street analyst forecast OCX's earnings for 2022 to be -$26,072,865, with the lowest OCX earnings forecast at -$26,072,865, and the highest OCX earnings forecast at -$26,072,865. On average, 1 Wall Street analyst forecast OCX's earnings for 2023 to be -$9,481,042, with the lowest OCX earnings forecast at -$9,481,042, and the highest OCX earnings forecast at -$9,481,042.

In 2024, OCX is forecast to generate $16,591,823 in earnings, with the lowest earnings forecast at $16,591,823 and the highest earnings forecast at $16,591,823.

What is OCX's revenue growth forecast for 2022-2024?

(NYSEMKT: OCX) ONCOCYTE's forecast annual revenue growth rate of 149.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.86%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.39%.

ONCOCYTE's revenue in 2022 is $8,027,000.On average, 1 Wall Street analysts forecast OCX's revenue for 2022 to be $3,105,041,150, with the lowest OCX revenue forecast at $3,105,041,150, and the highest OCX revenue forecast at $3,105,041,150. On average, 1 Wall Street analysts forecast OCX's revenue for 2023 to be $5,333,085,945, with the lowest OCX revenue forecast at $5,333,085,945, and the highest OCX revenue forecast at $5,333,085,945.

In 2024, OCX is forecast to generate $9,362,528,659 in revenue, with the lowest revenue forecast at $9,362,528,659 and the highest revenue forecast at $9,362,528,659.

What is OCX's forecast return on assets (ROA) for 2022-2024?

(NYSEMKT: OCX) forecast ROA is 11.34%, which is higher than the forecast US Biotechnology industry average of 9.49%.

What is OCX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year OCX price target, the average OCX price target is $3.22, with the highest OCX stock price forecast at $6.00 and the lowest OCX stock price forecast at $1.40.

On average, Wall Street analysts predict that ONCOCYTE's share price could reach $3.22 by May 24, 2023. The average ONCOCYTE stock price prediction forecasts a potential upside of 209.33% from the current OCX share price of $1.04.

What is OCX's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSEMKT: OCX) ONCOCYTE's current Earnings Per Share (EPS) is -$0.78. On average, analysts forecast that OCX's EPS will be -$0.22 for 2022, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at -$0.22. On average, analysts forecast that OCX's EPS will be -$0.08 for 2023, with the lowest EPS forecast at -$0.08, and the highest EPS forecast at -$0.08. In 2024, OCX's EPS is forecast to hit $0.14 (min: $0.14, max: $0.14).

What is OCX's forecast return on equity (ROE) for 2022-2024?

(NYSEMKT: OCX) forecast ROE is 29.13%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.